Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT03502850
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Testing effectiveness (Phase 2)Study completedNCT02094261
What this trial is testing

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 210
Testing effectiveness (Phase 2)Looking for participantsNCT05334277
What this trial is testing

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 280
Testing effectiveness (Phase 2)WithdrawnNCT01504542
What this trial is testing

Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Heat Biologics
Testing effectiveness (Phase 2)Study completedNCT02841579
What this trial is testing

Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M

Who this might be right for
Non-Small Cell Lung Cancer
MedSIR 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07410611
What this trial is testing

CtDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy

Who this might be right for
Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination
Hebei Medical University Fourth Hospital 84
Not applicableNot Yet RecruitingNCT07680907
What this trial is testing

A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen-Cilag Farmaceutica Ltda. 250
Early research (Phase 1)Active Not RecruitingNCT05163028
What this trial is testing

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Who this might be right for
Non Small Cell Lung CancerColorectal CancerPancreatic Cancer+4 more
HUYABIO International, LLC. 42
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05778149
What this trial is testing

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Who this might be right for
AumolertinibAnlotinibTP53+2 more
Tianjin Medical University Cancer Institute and Hospital 47
Testing effectiveness (Phase 2)UnknownNCT04636593
What this trial is testing

Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerStage III NSCLCEGFR Activating Mutation
First People's Hospital of Hangzhou 43
Large-scale testing (Phase 3)WithdrawnNCT06093503
What this trial is testing

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie
Early research (Phase 1)Looking for participantsNCT07315113
What this trial is testing

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients
Nuvectis Pharma, Inc. 18
Testing effectiveness (Phase 2)UnknownNCT02961270
What this trial is testing

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)UnknownNCT04785742
What this trial is testing

Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

Who this might be right for
Safety of Almonertinib
Sun Yat-sen University 40
Large-scale testing (Phase 3)Study completedNCT02474355
What this trial is testing

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 3,017
Large-scale testing (Phase 3)Looking for participantsNCT07005102
What this trial is testing

Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
AbbVie 854
Testing effectiveness (Phase 2)UnknownNCT06463171
What this trial is testing

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Shanghai Pulmonary Hospital, Shanghai, China 60
Not applicableStudy completedNCT02285361
What this trial is testing

GIOTRIF rPMS in Korean Patients With NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,272
Large-scale testing (Phase 3)Study completedNCT02044380
What this trial is testing

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 14
Next Page